SK284029B6 - Farmaceutická kompozícia na liečenie roztrúsenej sklerózy - Google Patents

Farmaceutická kompozícia na liečenie roztrúsenej sklerózy Download PDF

Info

Publication number
SK284029B6
SK284029B6 SK931-99A SK93199A SK284029B6 SK 284029 B6 SK284029 B6 SK 284029B6 SK 93199 A SK93199 A SK 93199A SK 284029 B6 SK284029 B6 SK 284029B6
Authority
SK
Slovakia
Prior art keywords
copolymer
cells
eae
day
fed
Prior art date
Application number
SK931-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK93199A3 (en
Inventor
Ruth Arnon
Michael Sela
Dvora Teitelbaum
Adrian Gilbert
Milka Linenberg
Rivka Riven-Kreitman
Original Assignee
Yeda Research And Development Co., Ltd-Company Of Israel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co., Ltd-Company Of Israel filed Critical Yeda Research And Development Co., Ltd-Company Of Israel
Publication of SK93199A3 publication Critical patent/SK93199A3/sk
Publication of SK284029B6 publication Critical patent/SK284029B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
SK931-99A 1997-01-10 1998-01-12 Farmaceutická kompozícia na liečenie roztrúsenej sklerózy SK284029B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (2)

Publication Number Publication Date
SK93199A3 SK93199A3 (en) 2000-11-07
SK284029B6 true SK284029B6 (sk) 2004-08-03

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
SK931-99A SK284029B6 (sk) 1997-01-10 1998-01-12 Farmaceutická kompozícia na liečenie roztrúsenej sklerózy

Country Status (19)

Country Link
EP (1) EP0975351B1 (de)
JP (1) JP4216342B2 (de)
KR (1) KR20000070058A (de)
CN (1) CN100528222C (de)
AT (1) ATE356608T1 (de)
AU (1) AU737287B2 (de)
BR (1) BRPI9807076B8 (de)
CA (1) CA2277365C (de)
CZ (1) CZ297983B6 (de)
DE (1) DE69837324T2 (de)
EA (1) EA003128B1 (de)
HK (1) HK1025737A1 (de)
HU (1) HU226612B1 (de)
IL (2) IL119989A0 (de)
NZ (1) NZ336690A (de)
PL (1) PL193300B1 (de)
SK (1) SK284029B6 (de)
WO (1) WO1998030227A1 (de)
ZA (1) ZA98214B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766498B2 (en) * 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
EP1552831B1 (de) * 1999-06-04 2009-01-07 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL153236A0 (en) * 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
ATE475883T1 (de) 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
US20040009169A1 (en) 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
WO2004066931A2 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
EA019998B9 (ru) 2009-08-20 2016-01-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Терапия глатирамером ацетатом с низкой кратностью
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CA2884267A1 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016172855A1 (zh) * 2015-04-28 2016-11-03 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
IL130820A (en) 2007-03-08
DE69837324D1 (de) 2007-04-26
HUP0001917A3 (en) 2001-12-28
JP4216342B2 (ja) 2009-01-28
BR9807076A (pt) 2000-05-02
WO1998030227A1 (en) 1998-07-16
CZ297983B6 (cs) 2007-05-16
CN1249690A (zh) 2000-04-05
EP0975351A1 (de) 2000-02-02
JP2001511121A (ja) 2001-08-07
EA199900621A1 (ru) 2000-02-28
AU5819598A (en) 1998-08-03
PL334566A1 (en) 2000-03-13
AU737287B2 (en) 2001-08-16
CA2277365A1 (en) 1998-07-16
PL193300B1 (pl) 2007-01-31
ZA98214B (en) 1999-08-11
EP0975351B1 (de) 2007-03-14
DE69837324T2 (de) 2007-11-29
CA2277365C (en) 2011-04-12
ATE356608T1 (de) 2007-04-15
HK1025737A1 (en) 2000-11-24
HUP0001917A2 (hu) 2000-10-28
EP0975351A4 (de) 2002-05-15
HU226612B1 (en) 2009-04-28
SK93199A3 (en) 2000-11-07
CN100528222C (zh) 2009-08-19
IL119989A0 (en) 1997-04-15
EA003128B1 (ru) 2003-02-27
BR9807076B1 (pt) 2013-10-29
NZ336690A (en) 2001-05-25
BRPI9807076B8 (pt) 2021-05-25
CZ243799A3 (cs) 2000-06-14
KR20000070058A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
SK284029B6 (sk) Farmaceutická kompozícia na liečenie roztrúsenej sklerózy
US6214791B1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO1998030227A9 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP3712260B2 (ja) 自己免疫疾患のバイスタンダー抑制
AU742970B2 (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
CN106668852B (zh) 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
JP2527749B2 (ja) 移植拒否反応抑制または自己免疫疾患治療用薬学的組成物
WO2011086470A1 (en) Treatment of multiple sclerosis
AU2003250892A1 (en) Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
US20100135953A1 (en) Method of treatment of age-related macular degeneration
RU2647438C2 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
HUT74900A (en) Treatment of autoimmune disease using oral tolerization and/or type i interferon
KR100435040B1 (ko) 티세포매개성질환들의치료를위한제제들및방법들
Sela Immunomodulatory vaccines against autoimmune diseases
US20110053855A1 (en) Ex vivo cell stimulation
US20030190323A1 (en) Preparations and methods for the treatment of T cell mediated diseases
US8349314B2 (en) Method of treating and/or preventing type II diabetes using Actinomycetales
US20180221434A1 (en) Multi-Peptide Composition
US20240238299A1 (en) Use of pyrrolopyrimidine compound
MXPA99006457A (en) Treatment of multiple sclerosisthrough ingestion or inhalation of copolymer-1
AU2772702A (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20180112